Journal
BIOACTIVE MATERIALS
Volume 8, Issue -, Pages 153-164Publisher
KEAI PUBLISHING LTD
DOI: 10.1016/j.bioactmat.2021.06.009
Keywords
Drug delivery systems; Theranosis; Magnetic hyperthermia; Magnetic resonance imaging; Melanoma
Funding
- NORTE 2020 (2014-2020 North Portugal Regional Operational Program) [NORTE-01-0145-FEDER-000019]
- ERDF (European Regional Development Fund) [NORTE-01-0145-FEDER-000019]
- European Union's Horizon 2020 Research and Innovation Programme [686009]
- TAMs-targeted and externally controlled nanotheranostics of triple-negative-breast-cancer (Nanother) [UTAPEXPL/NTec/0038/2017]
- Local specific treatment of triple-negativebreast-cancer through externally triggered target-less drug carriers (MagtargetON) project [NORTE-01-0145-FEDER-031142]
- FCT
- ERDF through NORTE2020
- 2014-2020 INTERREG Cooperation Programme Spain-Portugal (POCTEP) [0624_2IQBIONEURO_6_E]
- Raman4clinics COST Action [BM1401]
- Radiomag COST action [TD1402]
- Spanish MINECO [PI19/00349]
- Instituto de Salud Carlos III [CD19/00035]
- ERDF [PI19/00349]
Ask authors/readers for more resources
Currently, there are various promising strategies being developed to combine diagnostic and therapeutic capabilities in clinically effective formulations. In this study, a biocompatible magnetic lipid nanocomposite vehicle was created using an efficient and environmentally-friendly method to incorporate magnetic nanoparticles and an anticancer drug. The magnetic formulation showed excellent theranostic performance in vitro and in vivo, enhancing the anti-tumoral activity through a synergistic combination of magnetic hyperthermia effects and antimitotic therapy.
Nowadays, a number of promising strategies are being developed that aim at combining diagnostic and therapeutic capabilities into clinically effective formulations. Thus, the combination of a modified release provided by an organic encapsulation and the intrinsic physico-chemical properties from an inorganic counterpart opens new perspectives in biomedical applications. Herein, a biocompatible magnetic lipid nanocomposite vehicle was developed through an efficient, green and simple method to simultaneously incorporate magnetic nanoparticles and an anticancer drug (doxorubicin) into a natural nano-matrix. The theranostic performance of the final magnetic formulation was validated in vitro and in vivo, in melanoma tumors. The systemic administration of the proposed magnetic hybrid nanocomposite carrier enhanced anti-tumoral activity through a synergistic combination of magnetic hyperthermia effects and antimitotic therapy, together with MRI reporting capability. The application of an alternating magnetic field was found to play a dual role, (i) acting as an extra layer of control (remote, on-demand) over the chemotherapy release and (ii) inducing a local thermal ablation of tumor cells. This combination of chemotherapy with thermotherapy establishes a synergistic platform for the treatment of solid malignant tumors under lower drug dosing schemes, which may realize the dual goal of reduced systemic toxicity and enhanced anti-tumoral efficacy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available